MV
MVP.AU Medical Developments International Ltd
- Market cap
- AUD 41.1M
- P/E
- 36.5x
- P/B
- 0.74x
- ROE
- 1.1%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MVP.AU undervalued?
Graham numberMVP.AU trades 9.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medical Developments International Ltd fundamental analysis
11 of 22 checks passedROE 0/2
Low return on equity (1.1%), below 10%.
ROA 1/1
Return on assets (0.9%) is above the industry median (-8.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (537.6%) is above the industry median (42.8%).
Revenue Growth 1/2
Revenue grew 9.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (3.0%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 16.3x against interest expense, well covered.
PE vs Market 0/1
PE (36.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (36.5x) is above the industry median (21.9x).
PBV 1/1
Price to book (0.7x) is below the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 26.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Medical Developments International Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medical Developments International Ltd
Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory pr…
Full company profileMedical Developments International Ltd financial statements
Medical Developments International Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 18.3M | 17.5M | 20.9M | 22.5M | 25.3M | 21.9M | 32.3M | 33.1M | 39.1M | 42.6M |
| Gross Profit | 12.6M | 12.4M | 14.2M | 13.7M | 16.7M | -3.06M | -2.52M | 24.4M | 29.4M | 12.0M |
| Operating Income | 3.50M | 2.07M | 3.17M | 1.87M | -5.24M | -15.7M | -20.4M | -16.9M | 3.07M | 1.06M |
| EBITDA | 3.80M | 2.22M | 3.89M | 3.03M | -11.1M | -12.9M | -4.28M | -29.4M | 3.34M | 3.74M |
| Net Income | 1.82M | 243K | 1.04M | 379K | -12.6M | -12.4M | -5.61M | -41.0M | 94.0K | 626K |
| EPS | 0.03 | 0.00 | 0.02 | 0.01 | -0.18 | -0.17 | -0.07 | -0.47 | 0.00 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 41.8M | 49.5M | 84.8M | 94.9M | 100M | 101M | 109M | 59.2M | 66.4M | 68.6M |
| Total Liabilities | 20.2M | 28.5M | 40.2M | 51.5M | 31.9M | 44.1M | 28.2M | 13.4M | 11.3M | 12.8M |
| Shareholders' Equity | 21.6M | 21.0M | 44.6M | 43.3M | 68.3M | 57.3M | 81.3M | 45.7M | 55.1M | 55.8M |
| Cash & Short-term Investments | 1.69M | 794K | 25.6M | 15.5M | 36.3M | 20.4M | 24.7M | 9.74M | 17.8M | 21.4M |
| Total Debt | 429K | 9.25M | 182K | 3.36M | 3.05M | 2.81M | 2.56M | 2.29M | 1.99M | 1.67M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 4.01M | 1.79M | 21.3M | 172K | -8.81M | -10.7M | -16.5M | -10.8M | -43.0K | 5.75M |
| Capital Expenditure | 4.35M | 2.06M | 1.49M | 8.90M | 6.56M | 5.21M | 7.67M | 3.17M | 443K | 481K |
| Free Cash Flow | -342K | -268K | 19.8M | -8.73M | -15.4M | -15.9M | -24.2M | -13.9M | -486K | 5.27M |
| Ratios | ||||||||||
| ROE | 8.4% | 1.2% | 2.3% | 0.9% | -18.4% | -21.7% | -6.9% | -89.6% | 0.2% | 1.1% |
| ROA | 4.4% | 0.5% | 1.2% | 0.4% | -12.5% | -12.2% | -5.1% | -69.3% | 0.1% | 0.9% |
| Net Profit Margin | 9.9% | 1.4% | 5.0% | 1.7% | -49.7% | -56.5% | -17.3% | -123.7% | 0.2% | 1.5% |
| Debt to Equity | 0.02x | 0.44x | 0.00x | 0.08x | 0.04x | 0.05x | 0.03x | 0.05x | 0.04x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medical Developments International Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Mar 5, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 26.4M | 0.31 | - |
| 2022 | AUD 139K | 0.00 | - |
| 2021 | AUD 35.5M | 0.51 | - |
| 2020 | AUD 2.07M | 0.03 | 544.9% |
| 2019 | AUD 1.72M | 0.03 | 165.4% |
| 2018 | AUD 1.24M | 0.02 | 509.9% |
| 2017 | AUD 1.24M | 0.02 | 68.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Medical Developments International Ltd
- Insiders 25.16%
- Institutions 24.00%
- Public & others 50.84%
- Shares outstanding 113M
- Free float 75.0M
Top funds holding MVP.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 32.2K | 0.05% | - | Feb 2021 |
Medical Developments International Ltd company profile
- Company name
- Medical Developments International Ltd
- Ticker
- MVP.AU
- ISIN
- AU000000MVP2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- 4 Caribbean Drive, Scoresby, VIC, Australia, 3179
- Phone
- 61 3 9547 1888
- Website
- medicaldev.com
About Medical Developments International Ltd
Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory products, including space chambers, peak flow meters, portable nebulizers, and silicone face masks to aid sufferers of asthma and chronic obstructive pulmonary disease. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia.
Medical Developments International Ltd management
7- Mr. Brent MacGregorChief Executive Officer · born 1964
- Ms. Anita JamesChief Financial Officer
- Ms. Anastasia TanHead of Operations & Supply Chain
- Wayne PearceHead of Production
- Ms. Julianne AlexanderHead of Medical Affairs, Regulatory Affairs & Clinical Development
- Mr. Benson LeeHead of Commercial Operations
- Ms. Victoria SowemimoHead of Quality